Multiple Myeloma (MM) Recruiting Phase 2 Trials for DB01073 (Fludarabine)

Also known as: MULTIPLE MYELOMA (MM) / Multiple myeloma / Myeloma, Multiple / Multiple Myelomas / Multiple Myeloma(MM) / Plasma cell myelomas / Myelomatosis multiple / Peripheral plasma cell myeloma / Myelomatosis / Multiple myeloma myelomatosis / Plasma cell myeloma / Myeloma / Multiple myeloma with failed remission

IndicationStatusPhase
DBCOND0040908 (Multiple Myeloma (MM))Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02861417Timed Sequential Busulfan and Post Transplant Cyclophosphamide for Allogeneic TransplantationTreatment
NCT03018223Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCTPrevention
NCT01119066HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic MalignanciesTreatment
NCT02556931Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft MalignanciesTreatment
NCT03159702Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical TransplantationTreatment
NCT02581007RIC Transplant Using Haplo DonorsTreatment
NCT02661035Allo HSCT Using RIC for Hematological DiseasesTreatment
NCT02722668UCB Transplant for Hematological Diseases Using a Non Myeloablative PrepTreatment
NCT00309842Myeloablative Umbilical Cord Blood Transplantation in Hematological DiseasesTreatment
NCT02440464Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)Treatment